K Takahashi1, S Saito, Y Kamamura, M Katakawa, Y Monden. 1. Second Department of Surgery, School of Medicine, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770, Japan. tkeiji@clin.med.tokushima-u.ac.jp
Abstract
BACKGROUND: For patients with non-small cell lung cancer the TNM staging system and other conventional prognostic factors fail to predict accurately the outcome of treatment and survival. This study attempts to determine the prognostic value for survival of the proportions of CD4+ lymphocytes in the pleural cavity (PLY) of patients with resectable non-small cell lung cancer. METHODS: Lymphocytes in the pleural cavity separated from 51 patients with non-small cell lung cancer were examined by flow cytometry to measure the proportions of CD4+ PLY. Univariate and multivariate analyses were performed to assess the association between the proportion of CD4+ PLY and survival. RESULTS: The 5 year survival rate of patients with percentage CD4+ PLY of < or = 30% was 84% whereas that of patients with %CD4+ PLY > 30% was 26.9%. The difference in survival between the %CD4+ PLY < or = 30% and %CD4+ PLY > 30% groups was significant (p < 0.0001). The %CD4+ PLY in those who survived for 5 years was significantly lower than that in the patients who died within 5 years (p < 0.0001). The difference in survival between patients with stage IA and IB lung cancer with %CD4+ PLY < or = 30% and those with %CD4+ PLY > 30% was also significant (p = 0.015). Multivariate analysis showed that the proportion of CD4+ PLY (hazard ratio = 6.9, 95% CI 0.045 to 0.47) and nodal status (hazard ratio = 22.7, 95% CI 0.006 to 1.806) are significant and independent prognostic factors for the survival of patients with lung cancer. CONCLUSIONS: The proportion of CD4+ PLY may help to select patients who are likely to have a poorer prognosis after surgery and therefore may be suitable for consideration of adjuvant treatments. These results need confirmation in a larger prospective study.
BACKGROUND: For patients with non-small cell lung cancer the TNM staging system and other conventional prognostic factors fail to predict accurately the outcome of treatment and survival. This study attempts to determine the prognostic value for survival of the proportions of CD4+ lymphocytes in the pleural cavity (PLY) of patients with resectable non-small cell lung cancer. METHODS: Lymphocytes in the pleural cavity separated from 51 patients with non-small cell lung cancer were examined by flow cytometry to measure the proportions of CD4+ PLY. Univariate and multivariate analyses were performed to assess the association between the proportion of CD4+ PLY and survival. RESULTS: The 5 year survival rate of patients with percentage CD4+ PLY of < or = 30% was 84% whereas that of patients with %CD4+ PLY > 30% was 26.9%. The difference in survival between the %CD4+ PLY < or = 30% and %CD4+ PLY > 30% groups was significant (p < 0.0001). The %CD4+ PLY in those who survived for 5 years was significantly lower than that in the patients who died within 5 years (p < 0.0001). The difference in survival between patients with stage IA and IB lung cancer with %CD4+ PLY < or = 30% and those with %CD4+ PLY > 30% was also significant (p = 0.015). Multivariate analysis showed that the proportion of CD4+ PLY (hazard ratio = 6.9, 95% CI 0.045 to 0.47) and nodal status (hazard ratio = 22.7, 95% CI 0.006 to 1.806) are significant and independent prognostic factors for the survival of patients with lung cancer. CONCLUSIONS: The proportion of CD4+ PLY may help to select patients who are likely to have a poorer prognosis after surgery and therefore may be suitable for consideration of adjuvant treatments. These results need confirmation in a larger prospective study.
Authors: T Schöndorf; H Engel; C Lindemann; H Kolhagen; A A von Rücker; P Mallmann Journal: Cancer Immunol Immunother Date: 1997-04 Impact factor: 6.968
Authors: K Yasumoto; K Mivazaki; A Nagashima; T Ishida; T Kuda; T Yano; K Sugimachi; K Nomoto Journal: Cancer Res Date: 1987-04-15 Impact factor: 12.701
Authors: H Nakahashi; K Yasumoto; A Nagashima; H Yaita; S Takeo; A Motohiro; T Furukawa; K Inokuchi; K Nomoto Journal: Cancer Res Date: 1984-12 Impact factor: 12.701
Authors: Akihiro Shimotakahara; Joachim F Kuebler; Gertrud Vieten; Martin L Metzelder; Claus Petersen; Benno M Ure Journal: Pediatr Surg Int Date: 2007-05 Impact factor: 1.827
Authors: T A Zikos; A D Donnenberg; R J Landreneau; J D Luketich; V S Donnenberg Journal: Cancer Immunol Immunother Date: 2011-03-05 Impact factor: 6.968